Advertisement


Gabrielle A. Zecha, PA-C, MHA, and Aaron Begue, MS, RN, NP-C, OCN: The Role of Advanced Practice Providers in Oncology Care

NCCN 2021 Virtual Annual Conference

Advertisement

Gabrielle A. Zecha, PA-C, MHA, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, and Aaron Begue, MS, RN, NP-C, OCN, of Memorial Sloan Kettering Cancer Center, discuss how advanced practice providers are recruited and trained, ways to retain these valuable health-care professionals in the face of burnout, metrics to measure their productivity, and their future role in cancer care.



Related Videos

Issues in Oncology

Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers

Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vaccination rates, thus lowering the rate of cervical, genital, and head/neck cancers, all of which are linked to HPV.

Issues in Oncology

Robert Winn, MD, on Strategies for Reducing Racial Disparities in Oncology

Robert Winn, MD, of the Virginia Commonwealth University Massey Cancer Center, discusses the creation of a health equity report card to track how institutions are dealing with disparities in oncology care, ways to recognize bias in care, and adding health equity experts to guideline panels and other advisory groups.

Kidney Cancer

Eric Jonasch, MD, on Hereditary Renal Cell Carcinoma: Screening, Diagnosis, and Management

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the several hereditary renal cell cancer syndromes, the importance of surveillance for both renal and nonrenal manifestations, and the treatment options available.

Leukemia
Lymphoma

Jennifer R. Brown, MD, PhD, on Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors and their second-generation counterparts, the need for ways to manage disease progression on novel drugs, and minimal residual disease as a predictor of response.

Skin Cancer

April K. Salama, MD, on Managing Melanoma Brain Metastases

April K. Salama, MD, of Duke Cancer Institute, discusses the shift in recent years, as more effective therapies have become available, toward integrating systemic upfront treatment of patients with brain metastases from cutaneous melanoma; pivotal studies that have provided key data; and the need for a multidisciplinary approach incorporating medical, surgical, and radiation oncology.

Advertisement

Advertisement




Advertisement